To view this email as a web page, click here

Today's Rundown

Featured Story

MHRA flags risk of topical steroid withdrawal reactions

Topical steroids are a go-to option for treating eczema and psoriasis. However, the U.K. Medicines and Healthcare products Regulatory Agency has linked prolonged use to rare withdrawal reactions, leading it to call on manufacturers to update their labels.

read more

Top Stories

Investor snaps up drug delivery specialist Acino in bid to build regional pharma hub

Acino is changing hands again. Eight years after being taken private in a $439 million deal, the Swiss drug delivery specialist has been snapped up by an Abu Dhabi-based holding company that is making moves in pharma.

read more

Scancell taps PharmaJet for needle-free COVID-19 vaccine study

With one study suggesting needle phobia may account for 10% of COVID-19 vaccine hesitancy, there is potential for alternative delivery routes to clear a barrier to vaccination. Scancell has advanced its effort to provide an alternative by tapping PharmaJet for needle-free delivery technologies. 

read more

Virpax raises $40M to use delivery systems to improve pain drugs

Virpax Pharmaceuticals crept onto public markets earlier this year, grossing $18 million to support its work to use delivery systems to improve pain drugs. After seeing its share price soar in response to progress against COVID-19, Virpax filed to raise more money—only for its stock to come crashing back down to Earth.

read more

ESMO: In landmark win, Novartis' Kisqali extends breast cancer survival by one year. Can it challenge Pfizer's Ibrance?

Novartis’ breast cancer drug Kisqali already has two clinical wins under its belt showing a survival benefit over traditional treatment. Now, the company hopes a third, first-of-its-kind victory in newly diagnosed patients could give it a better shot at challenging Pfizer’s market-leading Ibrance. But a shift may not be up to the Swiss pharma.

read more

Resources

Whitepaper: Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease

Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes.

Whitepaper: Evaluating current manufacturing platforms for recombinant AAV production

Choose the right AAV platform for your viral vector-based therapy

Whitepaper: The Value of Precision Medicine Informatics Initiatives Research Findings

Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives.

Whitepaper: Challenging Tradition: The Argument for Integrated Commercialization to Improve Operational Agility

Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how.

Whitepaper: High-yield NK cell culture for allogeneic cell therapy applications

Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications.

Whitepaper: Five Trends to Watch in the European Market Access Environment

This white paper provides a concise overview of the trends currently shaping the market access environment in Europe, as well as the implications for biopharma companies.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Events